Whitney A. Spannuth

4.7k total citations
33 papers, 2.5k citations indexed

About

Whitney A. Spannuth is a scholar working on Molecular Biology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Whitney A. Spannuth has authored 33 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Reproductive Medicine and 8 papers in Obstetrics and Gynecology. Recurrent topics in Whitney A. Spannuth's work include Ovarian cancer diagnosis and treatment (12 papers), Angiogenesis and VEGF in Cancer (11 papers) and Endometrial and Cervical Cancer Treatments (7 papers). Whitney A. Spannuth is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), Angiogenesis and VEGF in Cancer (11 papers) and Endometrial and Cervical Cancer Treatments (7 papers). Whitney A. Spannuth collaborates with scholars based in United States, South Korea and Australia. Whitney A. Spannuth's co-authors include Anil K. Sood, Yvonne G. Lin, William M. Merritt, Aparna A. Kamat, Robert L. Coleman, Liz Y. Han, Charles N. Landen, David M. Gershenson, Susan K. Lutgendorf and Alpa M. Nick and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer Research and Clinical Cancer Research.

In The Last Decade

Whitney A. Spannuth

33 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Whitney A. Spannuth United States 25 1.2k 741 487 403 314 33 2.5k
William M. Merritt United States 29 1.7k 1.4× 1.0k 1.4× 469 1.0× 700 1.7× 168 0.5× 38 3.1k
Tsuyoshi Ohta Japan 24 822 0.7× 408 0.6× 273 0.6× 341 0.8× 144 0.5× 68 1.7k
Yuh-Lih Chang Taiwan 29 1.4k 1.1× 568 0.8× 70 0.1× 462 1.1× 48 0.2× 56 2.5k
Andelko Hrzenjak Austria 32 1.4k 1.1× 374 0.5× 81 0.2× 604 1.5× 160 0.5× 63 2.5k
Soumitro Pal United States 26 1.3k 1.0× 646 0.9× 78 0.2× 473 1.2× 32 0.1× 53 2.4k
Shu‐Wing Ng United States 22 1.1k 0.9× 250 0.3× 415 0.9× 698 1.7× 330 1.1× 41 2.2k
Luca Messerini Italy 35 1.0k 0.8× 1.1k 1.5× 94 0.2× 467 1.2× 46 0.1× 113 3.7k
Rong Shao China 21 981 0.8× 730 1.0× 52 0.1× 463 1.1× 27 0.1× 58 2.3k
Deborah M. Heuvelman United States 15 1.1k 0.9× 272 0.4× 63 0.1× 417 1.0× 58 0.2× 15 1.8k
Yongchang Chen China 23 1.4k 1.1× 813 1.1× 71 0.1× 465 1.2× 14 0.0× 76 2.5k

Countries citing papers authored by Whitney A. Spannuth

Since Specialization
Citations

This map shows the geographic impact of Whitney A. Spannuth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Whitney A. Spannuth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Whitney A. Spannuth more than expected).

Fields of papers citing papers by Whitney A. Spannuth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Whitney A. Spannuth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Whitney A. Spannuth. The network helps show where Whitney A. Spannuth may publish in the future.

Co-authorship network of co-authors of Whitney A. Spannuth

This figure shows the co-authorship network connecting the top 25 collaborators of Whitney A. Spannuth. A scholar is included among the top collaborators of Whitney A. Spannuth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Whitney A. Spannuth. Whitney A. Spannuth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Merritt, William M., Alpa M. Nick, Amy R. Carroll, et al.. (2010). Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer. Molecular Cancer Therapeutics. 9(4). 985–995. 47 indexed citations
2.
Spannuth, Whitney A., Lingegowda S. Mangala, Rebecca L. Stone, et al.. (2010). Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma. Molecular Cancer Therapeutics. 9(8). 2377–2388. 33 indexed citations
3.
Soliman, Pamela T., Michael Frumovitz, Whitney A. Spannuth, et al.. (2010). Lymphadenectomy during endometrial cancer staging: Practice patterns among gynecologic oncologists. Gynecologic Oncology. 119(2). 291–294. 101 indexed citations
4.
Stone, Rebecca L., Alpa M. Nick, Vahid Afshar‐Kharghan, et al.. (2010). Abstract 3436: Mechanisms of paraneoplastic thrombocytosis in ovarian carcinoma. Cancer Research. 70(8_Supplement). 3436–3436. 1 indexed citations
5.
Bryant, Christopher S., Sanjeev Kumar, Whitney A. Spannuth, et al.. (2010). Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer. Archives of Gynecology and Obstetrics. 283(2). 361–367. 12 indexed citations
6.
Merritt, William M., Christopher G. Danes, Mian M.K. Shahzad, et al.. (2009). Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biology & Therapy. 8(16). 1596–1603. 35 indexed citations
7.
Lin, Yvonne G., Anand Immaneni, William M. Merritt, et al.. (2008). Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth. Clinical Cancer Research. 14(17). 5437–5446. 51 indexed citations
8.
Mangala, Lingegowda S., Jansina Y. Fok, Yvonne G. Lin, et al.. (2008). Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma. Cancer Research. 68(14). 5849–5858. 88 indexed citations
9.
Spannuth, Whitney A., Alpa M. Nick, Nicholas B. Jennings, et al.. (2008). Functional significance of VEGFR‐2 on ovarian cancer cells. International Journal of Cancer. 124(5). 1045–1053. 124 indexed citations
10.
Spannuth, Whitney A., Anil K. Sood, & Robert L. Coleman. (2008). Angiogenesis as a strategic target for ovarian cancer therapy. Nature Clinical Practice Oncology. 5(4). 194–204. 121 indexed citations
11.
Merritt, William M., Yvonne G. Lin, Whitney A. Spannuth, et al.. (2008). Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth. JNCI Journal of the National Cancer Institute. 100(5). 359–372. 195 indexed citations
12.
Kim, Tae Jin, Murali K. Ravoori, Charles N. Landen, et al.. (2007). Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma. Cancer Research. 67(19). 9337–9345. 78 indexed citations
13.
Spannuth, Whitney A., Premal H. Thaker, & Anil K. Sood. (2007). Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish Woman with primary breast and ovarian cancer. American Journal of Obstetrics and Gynecology. 196(4). e6–e9. 7 indexed citations
14.
Moore, Kathleen N., Thomas J. Herzog, Sharyn N. Lewin, et al.. (2007). A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecologic Oncology. 105(2). 299–303. 67 indexed citations
15.
Kumar, S. Ram, R. Masood, Whitney A. Spannuth, et al.. (2007). The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. British Journal of Cancer. 96(7). 1083–1091. 80 indexed citations
16.
Halder, Jyotsnabaran, Yvonne G. Lin, William M. Merritt, et al.. (2007). Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma. Cancer Research. 67(22). 10976–10983. 181 indexed citations
17.
Landen, Charles N., Yvonne G. Lin, Guillermo N. Armaiz-Peña, et al.. (2007). Neuroendocrine Modulation of Signal Transducer and Activator of Transcription-3 in Ovarian Cancer. Cancer Research. 67(21). 10389–10396. 117 indexed citations
18.
Spannuth, Whitney A., Charles A. Leath, Warner K. Huh, et al.. (2006). A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecologic Oncology. 104(3). 591–595. 17 indexed citations
19.
Spannuth, Whitney A., Charles A. Leath, Michael Conner, & Ronald D. Alvarez. (2006). Inflammatory Pseudotumor of Pelvic Lymph Nodes. Obstetrics and Gynecology. 108(3). 779–782. 3 indexed citations
20.
Spannuth, Whitney A., Rodney P. Rocconi, Tyler O. Kirby, Warner K. Huh, & Michael Conner. (2005). Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report. Gynecologic Oncology. 98(1). 155–157. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William M. Merritt Breakdown of academic impact, for papers by Tsuyoshi Ohta Breakdown of academic impact, for papers by Yuh-Lih Chang Breakdown of academic impact, for papers by Andelko Hrzenjak Breakdown of academic impact, for papers by Soumitro Pal Breakdown of academic impact, for papers by Shu‐Wing Ng Breakdown of academic impact, for papers by Luca Messerini Breakdown of academic impact, for papers by Rong Shao Breakdown of academic impact, for papers by Deborah M. Heuvelman Breakdown of academic impact, for papers by Yongchang Chen
Rankless by CCL
2026